<

ABSCIENCES (EPA:AB) AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML)

Transparency directive : regulatory news

22/09/2021 18:09



Other stories

25/04/2024 21:52
25/04/2024 22:43
25/04/2024 23:26
25/04/2024 23:14
24/04/2024 23:30
25/04/2024 12:20
25/04/2024 12:32
25/04/2024 22:31
25/04/2024 20:48
25/04/2024 22:37
25/04/2024 18:42
25/04/2024 19:12
25/04/2024 19:15
25/04/2024 16:00
25/04/2024 18:59
25/04/2024 17:29
25/04/2024 12:17
25/04/2024 14:46
25/04/2024 22:55
25/04/2024 19:19
24/04/2024 09:00
24/04/2024 09:06
25/04/2024 20:24
25/04/2024 18:23
25/04/2024 18:02
25/04/2024 17:38
25/04/2024 23:45
25/04/2024 23:56
25/04/2024 23:43
26/04/2024 00:07
25/04/2024 14:18
25/04/2024 21:00
25/04/2024 19:30
25/04/2024 15:07
25/04/2024 06:00
25/04/2024 17:23
25/04/2024 23:38
25/04/2024 20:49